Prosecution Insights
Last updated: October 01, 2026

Examiner: HIBSHMAN, SARAH GRACE

Tech Center 1600 • Art Units: 1623 1693

This examiner grants 39% of resolved cases

Analysis

Sarah Grace Hibshman is an examiner in Art Unit 1623, part of Tech Center 1600. She has overseen 54 resolved cases, providing a moderate sample to identify her prosecution trends. Her allowance rate is 38.9 percent, which suggests a challenging environment for applicants. This 38.9 percent rate indicates that more than half of the applications she reviews do not reach allowance, requiring a focused and effective prosecution strategy. The 54 resolved cases establish an initial baseline for evaluating her examination style in Art Unit 1623.

The interview lift of 40.0 percent is a very strong positive sign for applicants. This lift suggests that direct communication with the examiner can significantly improve the chances of obtaining an allowance compared to the 38.9 percent baseline. By conducting an interview, practitioners can address the examiner's concerns more directly and potentially find a path to allowable subject matter. The 40.0 percent lift is a highly valuable data point for strategic planning in Tech Center 1600.

The median days to allowance for applications under her review is 1268. This timeline is a useful benchmark for managing expectations regarding the duration of the patent process. The 1268-day median pendency, combined with the 38.9 percent allowance rate, highlights the importance of using tools like the 40.0 percent interview lift to navigate the process. The 1268-day duration is a key metric for long-term planning in Art Unit 1623.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

38.9%
Allow Rate
-21.1% vs TC avg
84
Total Applications
+40.0%
Interview Lift
1268
Avg Prosecution Days
Based on 54 resolved cases, 2023–2026

Rejection Statute Breakdown

3.1%
§101 Eligibility
16.3%
§102 Novelty
41.3%
§103 Obviousness
24.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17768145 ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS Final Rejection YALE UNIVERSITY
18065228 REELIN/VEGF-C PRODUCTION/ACTIVATION PROMOTER AND SKIN EXTERNAL COMPOSITION USING THE SAME Final Rejection AMOREPACIFIC CORPORATION
17621114 USE OF NICOTINAMIDE MONONUCLEOTIDE (NMN) AND NICOTINAMIDE RIBOSIDE (NR) Final Rejection Kyoto University
17694404 DETECTING METHYLCYTOSINE AND ITS DERIVATIVES USING S-ADENOSYL-L-METHIONINE ANALOGS (xSAMS) Non-Final OA ILLUMINA CAMBRIDGE LIMITED
17922133 DRUG COMBINATION FOR TREATING DIABETES MELLITUS AND COMPLICATIONS THEREOF AND PHARMACEUTICAL COMPOSITION OF DRUG COMBINATION Non-Final OA Chengdu Chipscreen Pharmaceutical Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month